EGFR and neoplasm: This approach facilitates the direct targeting of EGFRvIII-positive tumor cells while also recruiting bystander T cells to attack EGFR-positive but EGFRvIII-negative tumor cells, thereby overcoming antigen heterogeneity and reducing toxicity to normal tissues [96].